# Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

> **NCT00604058** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 236 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Inactivated Poliomyelitis vaccine (IMOVAX)
- **BIOLOGICAL:** Inactivated Poliomyelitis vaccine (IMOVAX)

## Key facts

- **NCT ID:** NCT00604058
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-12
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604058, "Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00604058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*